Daniel J Crona
Overview
Explore the profile of Daniel J Crona including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azarniouch D, Crona D, Karnabi P, Bose B, Nachman P, Carrier M, et al.
Kidney Int Rep
. 2024 Oct;
9(10):3053-3056.
PMID: 39430178
No abstract available.
2.
Lines M, Kemper R, Wallace J, Alexander T, Echols C, Garner L, et al.
Eur J Haematol
. 2024 Jul;
113(5):584-592.
PMID: 38989562
Background: 6-mercaptopurine is a cornerstone of maintenance therapy for pediatric ALL. Response to 6MP is typically determined by the ANC. Therapeutic ANC range while receiving 6MP is between 500 and...
3.
Dunlap T, Weiner D, Kemper R, Kardouh M, DeVane S, Symonds A, et al.
J Clin Pharmacol
. 2023 May;
63(9):1026-1035.
PMID: 37122163
Busulfan is an alkylating agent used as part of conditioning chemotherapy regimens prior to allogeneic hematopoietic cell transplant (allo-HCT). Pharmacokinetic (PK)-guided test-dose strategies have been shown to improve the number...
4.
Derebail V, Zhu J, Crawford M, Garnier J, Martin K, Skinner S, et al.
Am J Kidney Dis
. 2022 Nov;
81(3):373-376.
PMID: 36328100
No abstract available.
5.
Bieberich A, Laitinen T, Maffuid K, Fatig 3rd R, Torrice C, Morris D, et al.
Sci Rep
. 2022 Jul;
12(1):12820.
PMID: 35896603
The 4-anilinoquin(az)oline is a well-known kinase inhibitor scaffold incorporated in clinical inhibitors including gefitinib, erlotinib, afatinib, and lapatinib, all of which have previously demonstrated activity against chordoma cell lines in...
6.
Austin C, Szeto A, Gupta A, Wiltshire T, Crona D, Kistler C
J Pharm Technol
. 2022 Jul;
38(4):195-201.
PMID: 35832565
Pharmacogenetics may explain a substantial proportion of the variation seen in the efficacy and risk profile of analgesosedative drugs and the incidence of delirium in critically ill adults. Conduct a...
7.
Quintanilha J, Etheridge A, Graynor B, Larson N, Crona D, Mitchell B, et al.
Clin Pharmacol Ther
. 2022 May;
112(2):364-371.
PMID: 35527502
Hypertension is a common bevacizumab-induced toxicity. No markers are available to predict patients at risk of developing hypertension. We hypothesized that genetic risk of essential hypertension, as measured by a...
8.
Quintanilha J, Geyer S, Etheridge A, Racioppi A, Hammond K, Crona D, et al.
Pharmacogenomics J
. 2022 Apr;
22(5-6):251-257.
PMID: 35484400
No biomarkers are available to predict toxicities induced by VEGFR TKIs. This study aimed to identify markers of toxicities induced by these drugs using a discovery-validation approach. The discovery set...
9.
Kistler C, Austin C, Liu J, Cauble M, Wise A, Patel S, et al.
J Am Geriatr Soc
. 2022 Feb;
70(5):1573-1578.
PMID: 35157308
No abstract available.
10.
Ratner L, Zhu J, Gower M, Patel T, Miller J, Cipriani A, et al.
Pharmacogenomics
. 2022 Jan;
23(3):183-194.
PMID: 35083934
To evaluate the potential impact of preemptive multigene pharmacogenomic (PGx) testing on medication prescribing in real-world clinical settings. Prescription frequencies for 65 medications with actionable PGx recommendations were collected in...